Latest news with #Cantargia
Yahoo
12 hours ago
- Business
- Yahoo
Otsuka to acquire Cantargia's CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in development as a drug candidate for autoimmune diseases. CAN10 targets interleukin-1 receptor accessory protein (IL1RAP) with potent inhibitory effects on pro-inflammatory cytokines within the interleukin 1 (IL-1) superfamily — IL-1, IL-33 and IL-36 — which are associated with various inflammatory or autoimmune diseases. Cantargia will receive a $33m upfront cash payment and up to an additional $580m in milestone payments, along with double-digit tiered earn-out payments from worldwide product sales. The transaction is subject to customary closing conditions and regulatory approval, with expectations set for completion in the third quarter of 2025. Otsuka Pharmaceutical president and representative director Makoto Inoue stated: "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our US subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our US subsidiary Jnana Therapeutics. 'This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." Otsuka Pharmaceutical will take full responsibility for developing and commercialising CAN10 across the globe. This entails directing all future development activities, seeking regulatory approvals, as well as exclusively managing manufacturing and sales operations worldwide. Otsuka Pharmaceutical also gains access to 3G5, a backup antibody. CAN10 is currently in a Phase I clinical trial. Cantargia interim CEO Damian Marron stated: 'This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune-inflammatory disorders. 'We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world-leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases.' "Otsuka to acquire Cantargia's CAN10 for autoimmune diseases" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
21 hours ago
- Business
- Yahoo
Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
Cantargia receives an upfront cash payment of USD 33 million. Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments from global product sales. Otsuka Pharmaceutical obtains worldwide rights for the development and commercialization of the CAN10 program. LUND, SE / / July 15, 2025 / Cantargia AB (publ) (Cantargia) (Nasdaq Stockholm:CANTA) today announced that it has entered into an agreement with Japanese healthcare company Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) pursuant to which Otsuka Pharmaceutical will acquire all Cantargia's assets related to its early-clinical stage CAN10 program. Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment and is eligible to up to additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales. The transaction, subject to customary closing conditions and regulatory approval, is expected to close in the third quarter of 2025. Otsuka Pharmaceutical will be fully responsible for the development and commercialization of CAN10 globally. Otsuka Pharmaceutical will direct and perform all future development, apply for regulatory approvals and exclusively carry out manufacturing and sales of the product worldwide. In addition to the CAN10 antibody, Otsuka Pharmaceutical acquires 3G5 [1] as a backup antibody and will also have exclusive first rights of negotiation regarding the next-generation IL-1RAP antibodies to be developed by Cantargia for a period of 2 years. CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines of the IL-1-super family: IL-1, IL-33 and IL-36. CAN10 is currently being evaluated in an ongoing phase 1 clinical trial. "This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune inflammatory disorders." said Cantargia's Interim Chief Executive Officer Damian Marron. "We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases." Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., Ltd., commented, "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our U.S. subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our U.S. subsidiary Jnana Therapeutics. This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." [1] 3G5 is a pre-clinical IL1RAP targeting antibody which is similar to CAN10. For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-15 08:45 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling of the cytokines of the IL1-super family via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. About Otsuka PharmaceuticalOtsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit AttachmentsCantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical SOURCE: Cantargia View the original press release on ACCESS Newswire
Yahoo
19-05-2025
- Health
- Yahoo
Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation
IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques. IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1, IL-33 and IL-36. IL1RAP targeted therapy offers a novel strategy to mitigate vascular inflammation. LUND, SE / / May 19, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the publication of preclinical results from IL1RAP targeting antibodies in models of vascular inflammation. Cytokines dependent on IL1RAP strongly affect human endothelial cells to induce release of proinflammatory mediators, attract immune cells and increase vascular permeability. These changes can be potently blocked by antibodies targeting IL1RAP. Also, IL1RAP levels in human atherosclerotic lesions correlate with various inflammatory markers, indicating translational possibility into human cardiovascular diseases (CVDs). The results are published in the Journal of the American Heart Association (JAHA). "IL1RAP and its ligands, IL-1, IL-33 and IL-36, are central for inflammation not only because of their effects on immune cells but also due to effects on other cells that respond to inflammation. The work now published show how IL1RAP-targeting antibodies can block inflammation by acting directly on endothelial cells and potentially reduce events important in several inflammatory diseases, including CVD"said David Liberg, CSO of Cantargia Vascular inflammation is a central part of several inflammatory diseases, including atherosclerosis. The current findings revealed that IL1RAP targeting antibodies inhibit the IL-1β, IL-33 and IL-36γ induced release of inflammatory and chemotactic mediators and genes related to endothelial activation and adhesion. Concordantly, endothelial permeability and neutrophil adhesion were inhibited by antibodies blocking IL1RAP. Analysis of human atherosclerotic plaques showed a correlation between the levels of IL1RAP and several of the inflammatory markers reduced by IL1RAP blockade, including interleukin-6 and -8 (IL-6 and IL-8). These data signify IL1RAP as a key regulator in vascular inflammation and in maintaining vascular integrity, which in turn implies targeting IL1RAP may have promising potential in several inflammatory diseases, including CVD. "Inflammation is a central hallmark of atherosclerosis, and our research shows that targeting IL1RAP inhibits important inflammatory markers central in atherosclerosis. The established collaboration with Cantargia is very valuable both for us and for development of therapeutic options within CVDs" said Associate Professor Karin H Franzén, Örebro University These data were generated in collaboration with Associate Professor Karin Franzén's research group at Örebro University. The article, titled "IL1RAP expression in human atherosclerosis - a target of novel antibodies to reduce vascular inflammation and adhesion", by Lindkvist et al., is available at Journal of the American Heart Associations website and at Cantargias website. For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: hidradenitis suppurativa (HS) and treatment resistant atopic dermatitis (AD). In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. Good safety is shown at the completed dose levels, and additional data are expected continuously during 2025. AttachmentsCantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation SOURCE: Cantargia View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Health
- Yahoo
Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation
IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques. IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1, IL-33 and IL-36. IL1RAP targeted therapy offers a novel strategy to mitigate vascular inflammation. LUND, SE / / May 19, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced the publication of preclinical results from IL1RAP targeting antibodies in models of vascular inflammation. Cytokines dependent on IL1RAP strongly affect human endothelial cells to induce release of proinflammatory mediators, attract immune cells and increase vascular permeability. These changes can be potently blocked by antibodies targeting IL1RAP. Also, IL1RAP levels in human atherosclerotic lesions correlate with various inflammatory markers, indicating translational possibility into human cardiovascular diseases (CVDs). The results are published in the Journal of the American Heart Association (JAHA). "IL1RAP and its ligands, IL-1, IL-33 and IL-36, are central for inflammation not only because of their effects on immune cells but also due to effects on other cells that respond to inflammation. The work now published show how IL1RAP-targeting antibodies can block inflammation by acting directly on endothelial cells and potentially reduce events important in several inflammatory diseases, including CVD"said David Liberg, CSO of Cantargia Vascular inflammation is a central part of several inflammatory diseases, including atherosclerosis. The current findings revealed that IL1RAP targeting antibodies inhibit the IL-1β, IL-33 and IL-36γ induced release of inflammatory and chemotactic mediators and genes related to endothelial activation and adhesion. Concordantly, endothelial permeability and neutrophil adhesion were inhibited by antibodies blocking IL1RAP. Analysis of human atherosclerotic plaques showed a correlation between the levels of IL1RAP and several of the inflammatory markers reduced by IL1RAP blockade, including interleukin-6 and -8 (IL-6 and IL-8). These data signify IL1RAP as a key regulator in vascular inflammation and in maintaining vascular integrity, which in turn implies targeting IL1RAP may have promising potential in several inflammatory diseases, including CVD. "Inflammation is a central hallmark of atherosclerosis, and our research shows that targeting IL1RAP inhibits important inflammatory markers central in atherosclerosis. The established collaboration with Cantargia is very valuable both for us and for development of therapeutic options within CVDs" said Associate Professor Karin H Franzén, Örebro University These data were generated in collaboration with Associate Professor Karin Franzén's research group at Örebro University. The article, titled "IL1RAP expression in human atherosclerosis - a target of novel antibodies to reduce vascular inflammation and adhesion", by Lindkvist et al., is available at Journal of the American Heart Associations website and at Cantargias website. For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: hidradenitis suppurativa (HS) and treatment resistant atopic dermatitis (AD). In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. Good safety is shown at the completed dose levels, and additional data are expected continuously during 2025. AttachmentsCantargia publishes promising preclinical results highlighting CAN10's potential to inhibit vascular inflammation SOURCE: Cantargia View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
Cantargia Publishes Interim Report for the First Quarter of 2025
LUND, SE / / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025. "The first quarter of 2025 has been rich in positive news for Cantargia. We continue to progress on all fronts, with strong news flow on all our projects and ongoing discussions regarding potential transactions that can be transformative for Cantargia. However, this has unfortunately been against a backdrop of macroeconomic turmoil and uncertainty which has weighed very heavily on biotech stock markets globally during the period", said Damian Marron, interim CEO of Cantargia. Significant events in the first quarter Damian Marron was appointed as interim CEO, following Göran Forsberg's resignation. Cantargia presented promising phase 1 results from CAN10's first multiple-dose cohort, as well as feedback from the FDA and clinical experts. The randomized phase 2 TRIFOUR study in triple-negative breast cancer was fully recruited. The first patient was enrolled in Cantargia's leukemia study with nadunolimab. Two abstracts on IL1RAP-ADC and nadunolimab's potential role in reducing chemotherapy induced neuropathy respectively will be presented at the AACR 2025 conference. Significant events after the end of the period Cantargia appointed Morten Lind Jensen as Chief Medical Officer. Treatment resistant atopic dermatitis (AD) was selected as second indication for CAN10's phase 2 program. Pharmacokinetic modelling using data from the single ascending dose groups and the first group receiving multiple subcutaneous doses of CAN10 confirms choice of every 4-week dosing in phase 2. Financial information First Quarter 2025 Net sales: SEK 0.0 M (0.0)Operating loss: SEK -45.0 M (-41.7)Loss after tax: SEK -46.9 M (-37.0)Loss per share: before and after dilution, SEK -0.19 (-0.20)Equity/assets ratio: 59 (78) per centCash and cash equivalents: SEK 103.9 M (107.6)Short-term investments: SEK 0.0 M (35.0) In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 13, at 3:00 p.m. CEST, where Cantargia's interim CEO, Damian Marron, Morten Lind Jensen (CMO), and Patrik Renblad (CFO), will present Cantargia and comment on the report, followed by a Q&A-session. If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: . If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: . The webcast will also be available on demand on Cantargia's corporate website: For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-13 07:00 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . AttachmentsInterim Report Jan Mar 2025 SOURCE: Cantargia View the original press release on ACCESS Newswire
